CLNN Clene Inc.
Clene Inc. (CLNN) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $0.43 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.5% since its last earnings release on August 14, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Clene Inc.
Clene, a clinical-stage biopharmaceutical company focused on neurodegenerative disease, is leading the way by using nanotechnology to treat bioenergetic failure, which underlies many neurological diseases.
Sector
Healthcare
Industry
Biotechnology